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A bs tr ac t
Background
Data suggest that the adjuvant use of bisphosphonates reduces rates of recurrence and 
death in patients with early-stage breast cancer. We conducted a study to determine 
whether treatment with zoledronic acid, in addition to standard adjuvant therapy, 
would improve disease outcomes in such patients.
Methods
In this open-label phase 3 study, we randomly assigned 3360 patients to receive stan-
dard adjuvant systemic therapy either with or without zoledronic acid. The zoledronic 
acid was administered every 3 to 4 weeks for 6 doses and then every 3 to 6 months to 
complete 5 years of treatment. The primary end point of the study was disease-free 
survival. A second interim analysis revealed that a prespecified boundary for lack 
of benefit had been crossed.
Results
At a median follow-up of 59 months, there was no significant between-group differ-
ence in the primary end point, with a rate of disease-free survival of 77% in each 
group (adjusted hazard ratio in the zoledronic acid group, 0.98; 95% confidence in-
terval [CI], 0.85 to 1.13; P = 0.79). Disease recurrence or death occurred in 377 patients 
in the zoledronic acid group and 375 of those in the control group. The numbers of 
deaths — 243 in the zoledronic acid group and 276 in the control group — were 
also similar, resulting in rates of overall survival of 85.4% in the zoledronic acid 
group and 83.1% in the control group (adjusted hazard ratio, 0.85; 95% CI, 0.72 to 1.01; 
P = 0.07). In the zoledronic acid group, there were 17 confirmed cases of osteonecrosis 
of the jaw (cumulative incidence, 1.1%; 95% CI, 0.6 to 1.7; P <0.001) and 9 suspected 
cases; there were no cases in the control group. Rates of other adverse effects were 
similar in the two study groups.
Conclusions
These findings do not support the routine use of zoledronic acid in the adjuvant man-
agement of breast cancer. (Funded by Novartis Pharmaceuticals and the National Can-
cer Research Network; AZURE Current Controlled Trials number, ISRCTN79831382.)
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Metastasis is a complex process that is dependent on both the biologic fea-tures of the primary tumor and cellular 
interactions within host tissues. In the bone micro-
environment, cancer cells stimulate osteoblasts to 
release receptor activator of nuclear factor κB li-
gand (RANKL), which binds to its receptor, RANK, 
on both precursor and mature osteoclasts. The 
resulting increase in osteoclastic bone resorption 
leads to the release of bone-derived growth factors 
that may provide a fertile environment for survival 
and growth of adjacent cancer cells.1 Thus, target-
ing bone-cell function provides a potential addi-
tional approach to preventing bone metastases as a 
component of standard adjuvant therapy.2 In many 
in vivo models, bisphosphonates prevent or delay 
metastasis.3 In addition, synergistic interactions 
between aminobisphosphonates and cytotoxic 
drugs have been shown in preclinical models.4,5
In patients with early-stage breast cancer, sev-
eral clinical trials have suggested that the adjuvant 
use of bisphosphonates reduces rates of recurrence 
and death.6-8 In addition, despite a lack of regula-
tory approval in most health care systems, the in-
clusion of a bisphosphonate as part of adjuvant 
therapy has become increasingly widespread. In 
this randomized, controlled, open-label phase 3 
study, called the Adjuvant Zoledronic Acid to Re-
duce Recurrence (AZURE) trial, we evaluated the 
adjuvant use of zoledronic acid in a broad popu-
lation of patients with stage II or III early-stage 
breast cancer.
Me thods
Study Patients
The research protocol and statistical analysis plan 
are available with the full text of this article at 
NEJM.org. To be eligible for the study, all the pa-
tients had to be at least 18 years of age, have a 
Karnofsky performance status of at least 80, and 
have a histologically confirmed breast cancer with 
axillary lymph-node metastasis (N1) or a T3–T4 
primary tumor. Complete primary tumor resection 
was mandated or intended after neoadjuvant ther-
apy. In addition, patients who were eligible for com-
pletion surgery (margin excision, mastectomy, or 
axillary lymph-node dissection) after completion of 
adjuvant chemotherapy could be included.
Patients were not eligible if there was clinical or 
imaging evidence of distant metastases or if com-
plete treatment of the primary breast tumor and 
regional lymph nodes was not possible. Other ex-
clusion criteria included a cancer diagnosis within 
the preceding 5 years, use of bisphosphonates dur-
ing the previous year, or a diagnosis of osteoporo-
sis or other bone disease likely to require bone-
targeted treatment. The serum creatinine level had 
to be less than 1.5 times the upper limit of the 
normal range. In 2005, after case reports of os-
teonecrosis of the jaw associated with bisphospho-
nates,9 an amendment was adopted to exclude 
patients with clinically significant, active dental 
problems or planned jaw surgery.
Randomization and Treatment
After providing written informed consent, patients 
were randomly assigned in a 1:1 ratio to receive 
standard adjuvant systemic therapy (control group) 
or standard adjuvant systemic therapy along with 
zoledronic acid. The zoledronic acid was admin-
istered immediately after each cycle of adjuvant 
chemotherapy in a 4-mg dose by intravenous infu-
sion every 3 to 4 weeks for 6 cycles and then every 
3 months for 8 doses, followed by 5 cycles on a 
6-month schedule for a total of 5 years. Dose ad-
justments for renal-function abnormalities were 
recommended in accordance with the product li-
cense. Daily oral supplements containing calcium 
(400 to 1000 mg) and vitamin D (200 to 500 IU) 
were recommended for all patients during the first 
6 months and were continued thereafter at the dis-
cretion of the treating physician.
External-beam radiotherapy to the breast and 
chest wall, with or without irradiation of regional 
lymph nodes, and adjuvant cytotoxic and endocrine 
treatments were given in accordance with standard 
protocols at each participating institution. After 
regulatory approval of trastuzumab for adjuvant 
use, the drug was allowed in patients with HER2-
positive tumors.
To minimize imbalances in tumor and treat-
ment characteristics between the study groups, the 
central, automated, 24-hour, computer-generated 
telephone randomization system incorporated the 
following variables: the number of involved axillary 
lymph nodes, clinical tumor stage, estrogen-recep-
tor status, type and timing of systemic therapy, 
menopausal status, statin use or nonuse, and study 
center.
Prerandomization investigations in accordance 
with institutional protocols included histologic 
confirmation of breast cancer; testing of hemato-
logic, renal, and hepatic function; and imaging 
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for the purpose of tumor staging. The follow-up 
schedule for both the zoledronic acid group and 
the control group included clinical assessment, 
physical examination, monitoring for adverse 
events, and measurement of hematologic, renal, 
and hepatic function. Investigations for possible 
recurrence were clinically directed as deemed ap-
propriate by the treating physician. Routine follow-
up imaging was not mandated.
The study treatment was discontinued in the 
event of a distant recurrence, unacceptable toxic-
ity, three consecutively missed treatments, the pa-
tient’s request, the treating physician’s recom-
mendation, or completion of 5 years of treatment. 
Continuation of the study medication was recom-
mended in the event of a locoregional recurrence 
and at the physician’s discretion after the diagno-
sis of a new primary cancer.
Study End Points
The primary end point of the study was disease-free 
survival, which was defined as an absence of dis-
tant recurrence, of any invasive locoregional recur-
rence (except for ipsilateral operable relapse within 
a conserved breast), and of death from any cause 
without recurrence. The secondary end point was 
overall survival. Prespecified subgroup analyses 
were based on variables included in the random-
ization.
We also performed exploratory analyses to in-
vestigate treatment effects on sites of first recur-
rence. After a protocol amendment was approved 
before the first interim analysis in 2008, we added 
another secondary end point: invasive-disease –free 
survival, which was defined according to the Stan-
dardized Definitions for Efficacy and End Points in 
Adjuvant Breast Cancer Trials (STEEP) guidelines.10 
(A complete definition is provided in the Supple-
mentary Appendix, available at NEJM.org.) The date 
of recurrence was defined as the date on which 
relapse was first suspected, rather than the date 
on which it was confirmed, to reduce the risk of 
ascertainment bias. On-site and telephone-based 
monitoring was performed to ensure that recur-
rence dates were backdated to the date on which 
the event was first suspected, when this date 
preceded clinical, histologic, or imaging confir-
mation.11
Study Oversight
The study was sponsored by the University of 
Sheffield and approved as a United Kingdom na-
tional trial by the Clinical Trials Advisory Awards 
Committee. Grant support was provided by No-
vartis Pharmaceuticals and was supplemented 
in the United Kingdom by the infrastructure of 
the National Cancer Research Network. Novartis 
Pharmaceuticals donated study supplies of zole-
dronic acid. The authors developed the study con-
cept, wrote the protocol, and performed and re-
viewed all analyses. The study was conducted in 
accordance with the protocol, with amendments 
to reduce the risk of osteonecrosis of the jaw 
and to inform both patients and dental practi-
tioners of this risk. The first author wrote the 
first draft of the manuscript, and all authors 
were involved in revision and approval of the 
manuscript. Novartis Pharmaceuticals was given 
an opportunity to comment on the manuscript, 
but all decisions on submission of the manu-
script for publication were made by the authors 
and the trial steering committee.
Statistical Analysis
A final analysis was planned after the primary 
end point (disease-free survival) had occurred in 
940 patients, on the basis of the recruitment of 
3300 patients during a 3-year period, an anticipat-
ed rate of disease-free survival of 75% at 3 years, 
and a 5% annual rate of loss to follow-up. It was 
estimated that these numbers would provide a 
power of 80% to detect a relative reduction of 17% 
in the rate of disease recurrence or death among 
patients receiving zoledronic acid, at a two-sided 
level of significance of 0.05, which would approx-
imate an absolute benefit of 3.7 percentage points.
A single interim analysis was planned after the 
primary end point had been reached in 470 pa-
tients, with a two-sided alpha level of 0.005.12 
After this analysis was performed, on the advice 
of the independent data and safety monitoring 
committee, no efficacy data were released. Be-
cause the rate of events contributing to the pri-
mary end point was lower than predicted (result-
ing in a combined rate of disease-free survival of 
85% at 3 years), an independent statistician who 
was unaware of the findings and was not in-
volved in the first interim analysis provided re-
vised stopping boundaries for both efficacy and 
lack of benefit that would allow timely release 
of a clinically important result. A second inter-
im analysis was planned after the primary end 
point had occurred in at least 705 patients, along 
with a 0.5% probability of declaring false positive 
results (one-sided) or a 5.0% probability of de-
claring negative results with the use of a group 
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sequential-design method.13 The analysis was car-
ried out on 752 events, resulting in an efficacy 
boundary for the hazard ratio of 0.833 (lower 
boundary) and a lack-of-efficacy boundary of 
0.936 (upper boundary). At this interim analy-
sis, the lack-of-efficacy boundary was crossed, 
and the committee recommended the release of 
results.
We used Kaplan–Meier survival curves to eval-
uate the rates of disease-free survival, invasive-
disease –free survival, and overall survival. We 
compared between-group differences using the 
log-rank test and a Cox proportional-hazards 
model to adjust for the minimization factors (ex-
cluding study center). We calculated rates of osteo-
necrosis of the jaw using cumulative incidence 
functions, in which deaths without a diagnosis 
of osteonecrosis of the jaw were considered to be 
competing-risk events and were compared with 
the use of the log-rank test. In a subgroup analy-
sis, we used the Cox proportional-hazards model 
to adjust for statistically significant factors in the 
overall analysis (estrogen-receptor status, lymph-
node involvement, and tumor stage).
All adverse events were evaluated in the safety 
population. No statistical testing was carried out 
on these end points, apart from confirmed cases 
of osteonecrosis of the jaw, since this disorder 
had been identified a priori as a clinically impor-
tant event linked to bisphosphonate use. All analy-
ses were performed with the use of SAS software, 
version 9.2 (SAS Institute).
3360 Patients underwent randomization
1679 Were assigned to control group
21 Received zoledronic acid during the 5-yr treat-
ment period in the absence of a DFS event
146 Received any bisphosphonate at any time
in the absence of a DFS event
1681 Were assigned to zoledronic acid group
1665 Received zoledronic acid 
16 Did not receive zoledronic acid
7 Were withdrawn from follow-up
5 Chose to discontinue drug
2 Had distant metastases
2 Had administrative error
1 Had intercurrent illness (requiring
noncancer-related surgery)
1 Had missing data
1 Was excluded owing to
withdrawal of full consent
to trial participation 4 days
after randomization
209 Had last follow-up visit more than 12 mo
before October 18, 2010
125 Had last follow-up visit 12 to <24 mo
36 Had last follow-up visit 24 to <36 mo
19 Had last follow-up visit 36 to <48 mo
17 Had last follow-up visit 48 to <60 mo
12 Had last follow-up visit ≥60 mo
227 Had last follow-up visit more than 12 mo
before October 18, 2010
131 Had last follow-up visit 12 to <24 mo
23 Had last follow-up visit 24 to <36 mo
29 Had last follow-up visit 36 to <48 mo
30 Had last follow-up visit 48 to <60 mo
14 Had last follow-up visit ≥60 mo
458 Discontinued zoledronic acid for reasons
other than death or distant metastases
267 Chose to discontinue drug
129 Were withdrawn by clinician
19 Missed 3 consecutive treatments
16 Had intercurrent illness or intervention
(including noncancer-related surgery)
5 Had abnormal renal function
2 Underwent cancer surgery
18 Had other reasons
2 Had missing data
1681 Were included in the analysis1678 Were included in the analysis
Figure 1. Enrollment and Outcomes.
Of the 16 patients in the zoledronic acid group who did not receive the assigned treatment, 2 had more than one 
reason. DFS denotes disease-free survival.
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R esult s
Study Patients
Between September 2003 and February 2006, a 
total of 3360 eligible women from 174 centers in 
seven countries were recruited. Of these patients, 
1681 were assigned to the zoledronic acid group 
and 1679 to the control group. Among the patients 
assigned to receive zoledronic acid, 1665 (99.0%) 
received at least one dose (Fig. 1). The tumor and 
treatment characteristics of the patients in the two 
study groups were well balanced (Table 1). A total 
of 95.5% of the patients received chemotherapy, 
which was planned to include an anthracycline in 
97.6% of the patients and a taxane in 24.2%; 208 
patients received neoadjuvant chemotherapy and 
3000 received postoperative chemotherapy.
When the database was locked, on October 18, 
2010, the median follow-up period was 59.3 months 
(interquartile range, 53.5 to 60.9) in the zoledronic 
acid group and 58.6 months (interquartile range, 
52.7 to 60.9) in the control group. The median time 
since the last follow-up contact for all surviving 
patients was 5.9 months (interquartile range, 3.8 to 
9.1), which was identical in the two groups.
Primary and Secondary End Points
At 5 years, 76.9% and 77.1% of the patients in the 
treatment and control groups, respectively, were 
alive and disease-free; 377 patients in the zoledronic 
acid group and 375 patients in the control group 
had recurrent disease or had died (adjusted hazard 
ratio in the zoledronic acid group, 0.98; 95% confi-
dence interval [CI], 0.85 to 1.13; P = 0.79) (Fig. 2A). 
Similarly, at 5 years, 75.4% and 75.3% of the pa-
tients in the treatment and control groups, re-
spectively, were alive and free of invasive disease; 
404 patients in the zoledronic acid group and 
403 patients in the control group had invasive 
disease or had died (adjusted hazard ratio, 0.98; 
95% CI, 0.85 to 1.12; P = 0.73) (Fig. 2B). The dis-
tributions of invasive-disease events were also 
similar in the two groups; 65.8% were distant 
recurrences, of which 230 were in bone (108 in 
the zoledronic acid group and 122 in the control 
group) (Table 1 in the Supplementary Appendix).
Despite the known effects of many cancer 
treatments on bone health and the risk of osteo-
porosis, only 146 patients in the control group 
(8.7%) received a bisphosphonate before reach-
ing the primary end point. To date, 519 patients 
have died: 243 in the zoledronic acid group (5-year 
overall survival rate, 85.4%) and 276 in the control 
group (5-year overall survival rate, 83.1%) (adjusted 
hazard ratio with zoledronic acid, 0.85; 95% CI, 
0.72 to 1.01; P = 0.07).
Subgroup Analyses
Prespecified subgroup analyses showed a consis-
tent lack of differential effect across the variables 
that were included in the randomization, with the 
Table 1. Characteristics of the Patients at Baseline.*
Characteristic
Zoledronic Acid
(N = 1681)
Control
(N = 1678)
Axillary lymph nodes — no. (%)
0 29 (1.7) 32 (1.9)
1–3 1041 (61.9) 1032 (61.5)
≥4 604 (35.9) 608 (36.2)
Unknown 7 (0.4) 6 (0.4)
Tumor stage — no. (%)
T1 542 (32.2) 523 (31.2)
T2 851 (50.6) 867 (51.7)
T3 227 (13.5) 228 (13.6)
T4 58 (3.5) 59 (3.5)
TX 3 (0.2) 1 (0.1)
Estrogen-receptor status — no. (%)
Positive 1319 (78.5) 1316 (78.4)
Negative 349 (20.8) 355 (21.2)
Unknown 13 (0.8) 7 (0.4)
Menopausal status — no. (%)
Premenopausal 751 (44.7) 752 (44.8)
Postmenopausal
≤5 yr 247 (14.7) 244 (14.5)
>5 yr 519 (30.9) 522 (31.1)
Status unknown 164 (9.8) 160 (9.5)
Planned systemic therapy — no. (%)
Endocrine therapy alone 76 (4.5) 75 (4.5)
Chemotherapy alone 362 (21.5) 360 (21.5)
Endocrine therapy plus chemotherapy 1243 (73.9) 1243 (74.1)
Planned type of chemotherapy — no./ 
total no. (%)
Anthracyclines 1567/1605 (97.6) 1564/1603 (97.6)
Taxanes 390/1605 (24.3) 385/1603 (24.0)
Timing of chemotherapy — no./ 
total no. (%)
Neoadjuvant 104/1605 (6.5) 104/1603 (6.5)
Postoperative 1501/1605 (93.5) 1499/1603 (93.5)
Statin use — no. (%) 97 (5.8) 101 (6.0)
* There were no significant differences between the two groups.
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exception of menopausal status. Significant hetero-
geneity of treatment effect (χ21 = 7.91, P = 0.005) 
on the rate of invasive-disease –free survival was 
observed between patients who had undergone 
menopause more than 5 years earlier and all 
other patients (those who were premenopausal or 
perimenopausal and those with unknown meno-
pausal status). At 5 years, among postmenopausal 
patients, the rates of invasive-disease –free survival 
were 78.2% in the zoledronic acid group and 71.0% 
in the control group (adjusted hazard ratio with 
zoledronic acid, 0.75; 95% CI, 0.59 to 0.96; P = 0.02); 
among all other patients, the rates were 74.1% in 
the zoledronic acid group and 77.2% in the control 
group (adjusted hazard ratio, 1.15; 95% CI, 0.97 to 
1.36; P = 0.11) (Fig. 3A and 3B). In addition, among 
patients who had undergone menopause more than 
5 years earlier, the 5-year overall survival rate was 
84.6% in the zoledronic acid group and 78.7% in 
the control group (adjusted hazard ratio, 0.74; 
95% CI, 0.55 to 0.98; P = 0.04), as compared with 
all other patients, for whom the rates were 85.7% 
in the zoledronic acid group and 85.1% in the con-
trol group (adjusted hazard ratio, 0.97; 95% CI, 
0.78 to 1.21; P = 0.81) (Fig. 3C and 3D). These dif-
ferences were independent of estrogen-receptor 
status, tumor stage, and lymph-node involvement.
With respect to distant skeletal recurrence, 
the effects of zoledronic acid did not differ sig-
nificantly between the two menopausal groups 
(χ21 = 0.14, P = 0.70). In contrast, for the other com-
ponents of invasive-disease –free survival, there 
was a consistent, significant difference in the ef-
fects of zoledronic acid according to menopaus-
al status, with an apparent benefit in postmeno-
pausal women and potential harm in all other 
women (χ21 = 14.00, P<0.001) (Fig. 1 in the Sup-
plementary Appendix).
Adverse Events
Dental adverse events were more frequent in the 
zoledronic acid group than in the control group, 
and investigators reported 26 cases of osteonecro-
sis of the jaw. Of these cases, 17 were confirmed on 
central review, all in the zoledronic acid group 
(rate, 1.1%; 95% CI, 0.6 to 1.7), including 3 cases 
occurring after metastases to bone. Of the 9 un-
confirmed cases, 4 did not conform to a standard 
definition of osteonecrosis of the jaw, and further 
information is awaited on 5 cases. The rate of frac-
ture was reduced in patients receiving zoledronic 
acid, with 175 fractures (65 in the zoledronic acid 
group and 110 in the control group) in 152 patients 
(60 in the zoledronic acid group and 92 in the 
control group). Rates of other adverse events were 
similar in the two study groups (Table 2, and Ta-
bles 2 and 3 in the Supplementary Appendix). 
Most serious adverse events were related to che-
motherapy or other cancer treatments. No sig-
nificant difference was seen in rates of neutro-
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Figure 2. Disease-free Survival and Invasive-Disease–free Survival 
in the Intention-to-Treat Population.
Panel A shows the proportion of patients who were alive without a recur-
rence of disease, and Panel B shows the proportion of patients who were 
alive without invasive disease at 5 years and beyond. The I bars represent 
95% confidence intervals.
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penic fever. Chemotherapy dose reductions and 
delays were similar in the two study groups (data 
not shown).
Discussion
Clinical trials of adjuvant bisphosphonates in pa-
tients with early-stage breast cancer have had 
variable results. A reduction in bone metastases 
and improved overall survival were reported in 
two trials of oral clodronate.6,7 However, two other 
trials showed no benefit.14,15 More recently, in 
the Austrian Breast and Colorectal Cancer Study 
Group 12 (ABCSG-12) trial (ClinicalTrials.gov num-
ber, NCT00295646) involving 1803 premenopausal 
women with estrogen-receptor–positive breast 
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Figure 3. Invasive-Disease–free Survival and Overall Survival According to Menopausal Status.
Shown are the proportions of patients who were alive and free of invasive disease (Panels A and B) or alive with or without recurrence 
(Panels C and D) according to menopausal status (postmenopausal [defined as >5 years since menopause] vs. premenopausal, peri-
menopausal, or unknown). The I bars represent 95% confidence intervals.
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cancer who were treated with goserelin and ei-
ther tamoxifen or anastrozole, the administration 
of zoledronic acid every 6 months for 3 years re-
duced the risk of disease recurrence by about one 
third.8 In addition, several large randomized tri-
als addressing the question have completed ac-
crual and are in the follow-up phase.
In our study, no improvement was seen in the 
rate of disease-free survival, the primary end point 
of the study; rates of invasive-disease–free survival 
and overall survival were similar in the two study 
groups. This primary result is unlikely to change 
with further follow-up and appears to differ mark-
edly from the findings of Gnant and colleagues 
in the ABCSG-12 study.8 However, there are im-
portant differences between the two study popu-
lations. In the ABCSG-12 study, all the patients 
started receiving goserelin and endocrine therapy 
(resulting in a rapid suppression of reproductive 
hormones) before the initiation of bisphosphonate 
treatment; in addition, the patients had disease 
with a good prognosis, and less than 5% received 
chemotherapy. In contrast, the premenopausal pa-
tients in our study had a less favorable prognosis, 
more than 95% received chemotherapy, and all had 
premenopausal levels of reproductive hormones 
at study entry. Only three of the premenopausal 
patients (0.2%) in our study received goserelin.
In a prespecified analysis, our finding of a 
possible benefit of zoledronic acid in patients who 
had undergone menopause more than 5 years 
before study entry is intriguing. From an endo-
crine perspective, the postmenopausal patients in 
our study were similar to the goserelin-treated 
patients in the ABCSG-12 study,8 who had low 
levels of reproductive hormones at study entry. 
The curves for rates of disease-free survival in 
the postmenopausal subgroup diverged rapidly 
(absolute difference, 3 percentage points at 1 year 
and 5 percentage points at 2 years) and showed 
a small but significant survival advantage for 
patients who received zoledronic acid. Further-
more, the use of zoledronic acid appeared to 
have divergent effects on metastasis to visceral 
and locoregional sites according to menopausal 
status. Our analysis of the interaction of the 
various components of invasive-disease–free sur-
vival suggests a systemic effect of zoledronic 
Table 2. Serious Adverse Events in the Safety Population.*
Serious Adverse Event
Zoledronic Acid
(N = 1686)
Control
(N = 1666)
Difference
(95% CI)†
number of patients (percent) percentage points
Neutropenia
Septic 160 (9.5) 159 (9.5) 0.1 (−2.0 to 1.9)
Any 41 (2.4) 49 (2.9) −0.5 (−1.6 to 0.6)
Pyrexia 37 (2.2) 24 (1.4) 0.8 (−0.1 to 1.7)
Vomiting 35 (2.1) 23 (1.4) 0.7 (−0.2 to 1.6)
Lower respiratory infection 24 (1.4) 33 (2.0) −0.6 (−1.4 to 0.3)
Central-catheter infection 24 (1.4) 21 (1.3) 0.2 (−0.6 to 0.9)
Cellulitis 21 (1.2) 21 (1.3) 0.0 (−0.8 to 0.7)
Pulmonary embolus‡ 25 (1.5) 13 (0.8) 0.7 (0.0 to 1.4)
Osteonecrosis of the jaw
Confirmed§ 17 (1.1) 0 NA
Suspected 9 0 NA
* Listed are serious adverse events that occurred in more than 1% of patients in either study group in the safety popula-
tion, which is defined in the Supplementary Appendix. Adverse events that have been classified according to organ sys-
tem and grade are listed in Tables 2 and 3 in the Supplementary Appendix. NA denotes not applicable.
† Positive values indicate a greater frequency of the event in the zoledronic-acid group. Between-group differences were 
calculated before the rounding of percentages.
‡ In addition to the cases of pulmonary embolus that were classified as serious adverse events, 3 cases (1 in the zole-
dronic-acid group and 2 in the placebo group) were reported as adverse events, for a total of 41 patients with pulmo-
nary embolus (1.5% in the zoledronic acid group and 0.9% in the control group; absolute difference, 0.6 percentage 
points; 95% confidence interval, -0.1 to 1.4).
§ P<0.001.
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acid that operates differently according to meno-
pausal status and that is distinct from any effect 
in bone (Fig. 1 in the Supplementary Appendix). 
The explanation for this finding is unclear, but 
perhaps bone provides a sanctuary for cancer 
cells, and after treatment with zoledronic acid, 
the ability of cancer cells to disseminate to 
other body sites is dependent on the presence of 
reproductive hormones.
The apparent early benefits seen in the post-
menopausal subgroup suggest that the initial 
phase of treatment, when zoledronic acid is com-
bined with chemotherapy, may be most impor-
tant. During neoadjuvant chemotherapy with zole-
dronic acid, an increased tumor response in the 
breast16 and a reduced number of disseminated 
tumor cells in the bone marrow17 have been ob-
served, suggesting positive interactions between 
zoledronic acid and chemotherapy.
Adjuvant chemotherapy would be expected to 
induce menopause in a high proportion of women 
over the age of 40 years. However, it may take many 
months for chemotherapy to affect reproductive 
hormone levels, and despite causing amenorrhea, 
chemotherapy may not result in complete ovar-
ian suppression. It is unclear how the endocrine 
environment in bone might influence interactions 
between chemotherapy and zoledronic acid. How-
ever, as levels of ovarian-derived inhibin decline 
after menopause, the control of bone-cell function 
changes from primary regulation through effects 
of inhibins on osteoblasts to control by locally 
produced activin interacting with bone morpho-
genic proteins and noggin to drive bone turnover.18
In our study, zoledronic acid had no demon-
strable effect on chemotherapy-associated toxic 
effects. A full description of the adverse-event 
profile in this trial has been reported previous-
ly.19 Confirmed osteonecrosis of the jaw occurred 
in 1.1% of patients who were treated with zole-
dronic acid, with an additional nine suspected 
cases. Resolution of osteonecrosis of the jaw was 
seen in some cases, but the observed frequency 
of this complication in our study was higher 
than that reported in other studies of zoledronic 
acid in patients receiving adjuvant therapy.8,20 
This discrepancy presumably reflects the more 
intensive schedule of zoledronic acid and greater 
use of chemotherapy in our study. On the positive 
side, zoledronic acid was associated with a re-
duction in rates of fracture, particularly among 
patients who had a disease recurrence.
In conclusion, our findings do not support the 
routine use of zoledronic acid as adjuvant ther-
apy in unselected patients with early-stage breast 
cancer. Further investigation into the possible in-
teraction between zoledronic acid and reproduc-
tive hormones is required. For postmenopausal 
women, the use of bisphosphonates remains ap-
propriate for the prevention of treatment-induced 
bone loss and osteoporosis and might have bene-
ficial effects on disease outcomes. The optimum 
schedule, duration, and type of bisphosphonate 
therapy remain unknown.
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